tetrabenazine

Tetrabenazine (Ro 1-9569) is a former antipsychotic drug used to treat various movement disorders. It inhibits neurotransmitter uptake into adrenergic storage vesicles and serves as a high-affinity label for the vesicle transport system.

Tetrabenazine Racemate (Rubigen) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine Racemate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.

(+)-Tetrabenazine ((3R,11bR)-Tetrabenazine) is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Tetrabenazine Metabolite ((-)-β-HTBZ), a vesicles monoamine transporter 2 (VMAT2) inhibitor, is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite has a high affinity for VMAT2 with a Ki of 13.4 nM. Tetrabenazine Metabolite is often used to study chorea associated with Huntington's disease and other hyperactivity disorders.

Tetrabenazine D6 is the deuterium-labeled Tetrabenazine. Tetrabenazine is a VMAT-inhibitor used for the treatment of hyperkinetic movement disorder.

Tetrabenazine methanesulfonate is a medicine formerly utilized as an antipsychotic and therapy for various movement disorders. Tetrabenazine methanesulfonate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affin

(3R,11bR)-Tetrabenazine-d6 is a deuterated compound of (3R,11bR)-Tetrabenazine. (3R,11bR)-Tetrabenazine has a CAS number of 1026016-83-0. (+)-Tetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Trans (2,3)-Dihydrotetrabenazine is a Tetrabenazine metabolite, shows inhibition activity on vesicular monoamine transporter (VMAT2).

Deutetrabenazine metabolite M4 is believed to be related to its effect as a reversible depletion of monoamines from nerve terminals. The major circulating metabolites of Deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake

(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.

(2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. It suppresses the vesicular transport of monoamine neurotransmitters, such as dopamine and serotonin, leading to reduced release into the synaptic cleft. This compound holds potential for research in Huntington's disease and other hyperkinetic movement disorders.

JJC8-089, a dopamine transporter (DAT) inhibitor, might enhance motivation-related dysfunctions by increasing effortful behavior in goal-oriented activities. This compound significantly counteracted the low-effort effects induced in rats by the VMAT-2 inhibitor Tetrabenazine, and elevated the selection of high-effort fixed ratio 5 lever presses associated with food intake.